Success Story: EB1A Approved in 21 Days under Premium Processing! Our Firm Assisted a Pakistani Assistant Professor in Securing Success
Client’s Testimonial:
"I want to express my sincere and heartfelt gratitude to the entire Chen Immigration team and especially my case attorney, K., for the brilliant work, expertise, and leadership in getting my case approved. K. and team truly prepared an exceptional application. Each section and sentence was carefully and skillfully crafted, with great attention to detail. Thank you so much for clarifying each and every question I had throughout the process (and I know I had many!!). This decision has really come as a blessing for my family and me...and I am truly grateful to the entire Chen team. You all are the best!”
On January 26th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an Assistant Professor in the Field of Epidemiology (Approval Notice).
General Field: Epidemiology
Position at the Time of Case Filing: Assistant Professor
Country of Origin: Pakistan
State of Residence at the Time of Filing: Texas
Approval Notice Date: January 26th, 2026
Processing Time: 21 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (NAILG) is pleased to share the successful approval for an assistant professor in epidemiology. The client, who holds a Ph.D. in population health sciences, approached NAILG seeking support in securing permanent residency through the EB1A (Alien of Extraordinary Ability) category.
After a thorough review of the client's achievements and impact, we prepared a compelling petition that resulted in the approval of the I-140 EB1A filing without any Request for Evidence (RFE) in 21 days under premium processing. This approval underscores the client's extraordinary influence in health equity research and population health management.
Accomplishments and Expertise
The client has established a strong reputation as a leading researcher in epidemiology, with particular expertise in chronic disease epidemiology and social determinants of health (SDOH). Much of the client's work focuses on developing novel epidemiological frameworks to examine health disparities and to improve the management of leading chronic diseases, such as obesity, chronic obstructive pulmonary disease, and cardiovascular disease. The client's contributions have been especially influential in developing comprehensive methodological approaches to identify and quantify social disadvantages across multiple SDOH categories, including economic stability, food insecurity, and healthcare access.
In support of the EB1A petition, NAILG highlighted several objective achievements, including:
- 67 peer-reviewed journal articles (with 11 first-authored or co-first-authored), 33 published abstracts (including 4 first-authored), 1 first-authored book chapter, 5 technical reports (with 1 first-authored)
- 11 completed peer reviews, reflecting the client's authority and recognition in the field
- 2,520 citations, demonstrating extensive reliance on the client's work by other independent scientists
- Major funding from the American Heart Association, Duke Clinical Research Institute, Patient Centered Outcomes Research Institute, and National Institutes of Health
Letters of Recommendation
To further support the petition, we obtained two expert letters of recommendation from highly regarded professionals in epidemiology and cardiovascular medicine. One expert has stated that:
"[The Client] has proven [The Client]’s expertise through [The Client]’s impactful research into epidemiological frameworks involving the SDOH, as well as [The Client]’s valuable peer review contributions."
EB1A Approval and Outlook
The client's continued work in chronic disease epidemiology and health equity research promises to support improved cardiovascular disease prevention, reduced health disparities, and improved population health outcomes, areas of strong national importance in the United States.
NAILG is honored to have represented the client in this successful EB1A petition and looks forward to seeing the continued contributions the client will make to advancing public health and scientific discovery.